Learning Center for the MDS Foundation
2018 Breakfast Symposium

San Diego Convention Center
Room 6A
San Diego, California
7:00 am – 11:00 am

Register Now

ACTIVITY OVERVIEW
This symposium will describe recent advances in our understanding of the pathophysiology of myelodysplastic syndromes and related myeloid neoplasms, and how these advances are being translated into more effective treatments for these patients.

TARGET AUDIENCE
This activity is intended for physicians, oncology nurses, nurse practitioners, physician assistants, pharmacists and other health care professionals interested in the treatment and management of patients with Myelodysplastic Syndromes.

LEARNING OBJECTIVES

Upon completion of the educational activity, participants should be able to:

  • Describe how to use molecular genetics in diagnostic and prognostic evaluation of MDS.
  • Discuss important factors when comparing High-risk MDS and AML.
  • Recite the pathophysiology of myeloid neoplasms associated with spliceosome mutations.
  • Explain the future of epigenetic therapy.
  • Discuss recent advances in allogeneic transplantation and prospects for cellular therapy.

FACULTY

Stephen Nimer, MD – MDSF Chairman

Director, Sylvester Comprehensive Cancer Center
Professor of Medicine, Biochemistry & Molecular Biology
University of Miami Miller School of Medicine
Miami, Florida

Mario Cazzola, MD – Symposium Co-Chair

Professor of Hematology
Department of Molecular Medicine, University of Pavia
Chief, Division of Hematology
Department of Hematology Oncology, Fondazione IRCCS Policlinico S. Matteo
Pavia, Italy

Moshe Mittelman, MD – Symposium Co-Chair

Director, Department of Medicine
Tel-Aviv Sourasky Medical Center
Tel-Aviv, Israel

Elsa Bernard, PhD

Memorial Sloan Kettering Cancer Center
New York City, New York

Michael Heuser, MD

Heisenberg Chair for Molecular Therapies in Hematology
Hannover Medical School
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation
Hannover, Germany

Ghulam J. Mufti, DM, FRCP, FRCPath

Head of Department
Professor of Haemato Oncology in Haematological Medicine
King’s College London & King’s College Hospital
London, United Kingdom

Michael Savona, MD

Professor of Medicine
Director of Hematology Research
Director, Hematology Early Therapeutics Program
Vanderbilt-Ingram Cancer Center
Department of Medicine, Division of Hematology & Oncology
Nashville, Tennessee, United States

Matthew Walter, MD

Professor
Washington University School of Medicine in St. Louis
Department of Medicine, Oncology Division
St. Louis, Missouri

AGENDA

Friday, November 30, 2018
7:00 – 7:30 am Breakfast
7:30 – 11:00 am Symposium
SCIENTIFIC PROGRAM
Co-Chairs:
Mario Cazzola, MD (Pavia, Italy)
Moshe Mittelman, MD (Tel Aviv, Israel)
7:30 – 7:35 am Welcome and Overview – About the MDS Foundation, Inc.
Stephen Nimer, MD (MDSF Chairman)
Sylvester Comprehensive Cancer Center University of Miami
Miami, Florida, USA
7:35 – 7:40 am Program Overview and Objectives
Moshe Mittelman, MD
Tel-Aviv Sourasky Medical Center
Tel-Aviv, Israel
7:40 – 8:15 am Update of Mutational Impact on Diagnostic and Prognostic Evaluation of MDS
Elsa Bernard, PhD
Memorial Sloan Kettering Cancer Center
New York City, New York, United States
8:15 – 8:50 am High-Risk MDS and AML: One or Two Diseases?
Michael Heuser, MD
Hannover Medical School
Hannover, Germany
8:50 – 9:25 am Myeloid Malignancies Associated with Spliceosome Mutations
Matthew Walter, MD
Washington University School of Medicine in St. Louis
St. Louis, Missouri, United States
9:25 – 10:00 am Epigenetic Therapies: What’s Next?
Michael Savona, MD
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
10:00 – 10:35 am Recent Advances in Allogeneic Transplantation and Prospects for Cellular Therapy
Ghulam Mufti, DM, FRCP, FRCPath
King’s College London & King’s College Hospital
London, United Kingdom
10:35 – 11:00am Questions/Answers/Discussion

CRITERIA FOR SUCCESS

Statements of credit will be awarded based on the participant’s attendance, participation in the pre/post-test and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at https://www.mds-foundation.org/learning-center/mds-2018/. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this CME/CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

ACCREDITATION

AKH LOGO
CME/CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare

PHYSICIANS

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and the Myelodysplastic Syndromes Foundation, Inc. (MDSF). AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHYSICIAN ASSISTANTS

NCCPA accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

PHARMACY

ACPE LOGO

AKH, Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AKH, Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 3.5 contact hour(s) (0.35 CEUs). UAN 0077-9999-18-025-L04-P.

NURSING

AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity is awarded 3.5 Contact Hours.

Activity is jointly-provided by AKH Inc., Advancing Knowledge in Healthcare and the Myelodysplastic Syndromes Foundation, Inc. (MDSF).

COMMERCIAL SUPPORT

This activity is supported by an educational grant from Celgene Corporation, Onconova Therapeutics, Inc. and Takeda Oncology.

AMERICANS WITH DISABILITIES ACT

AKH Inc, Advancing Knowledge in Healthcare fully intends to comply with the legal requirements of the Americans with Disabilities Act.  If you need assistance, please notify AKH at 904-683-8843 at least two weeks prior to the activity.

*Activity and faculty subject to change

Message Board
Review answers to commonly asked questions or get answers to your questions from an MDS expert